<DOC>
	<DOCNO>NCT00276549</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine docetaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study well give gemcitabine together docetaxel work treat patient metastatic prostate cancer .</brief_summary>
	<brief_title>Gemcitabine Docetaxel Treating Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine objective response rate toxicity patient androgen-independent metastatic prostate cancer treat gemcitabine hydrochloride docetaxel . OUTLINE : This open-label study . Patients receive gemcitabine hydrochloride IV 30 minute day 1 8 follow docetaxel IV 60 minute day 8 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically least 5 year . PROJECTED ACCRUAL : A total 36 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Androgenindependent metastatic prostate cancer evidence clinical , radiographic , biochemical progression set castrate level testosterone ( &lt; 50 mg/dL ) No androgenindependent prostate cancer rise prostatespecific antigen ( PSA ) without clinical radiographic evidence metastasis Clinical radiographic evidence metastatic disease rise PSA measure 2 time ≥ 1 week interval allow Antiandrogen therapy must stop least 4 week ( flutamide ) 6 week ( bicalutamide nilutamide ) prior study entry evidence either rise PSA ( baseline ) measure twice least 2 week apart radiographic evidence disease progression Testicular androgen suppression ( &lt; 50 mg/dL ) must maintain either luteinizinghormone releasinghormone ( LHRH ) therapy bilateral orchiectomy No clinical evidence CNS metastases PATIENT CHARACTERISTICS : ECOG performance status 02 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin ≤ 1.5 mg/dL AST ALT ≤ 2 time normal Creatinine &lt; 2 mg/dL No history severe uncontrolled congestive heart failure ( CHF ) , ventricular dysrhythmias , severe cardiovascular disease ( American Heart Association class III IV ) Diseasefree prior malignancy ≥ 5 year , exception curatively treat basal cell squamous cell carcinoma skin lowgrade , lowstage bladder cancer No active infection parenteral antibiotic within 7 day study entry Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics No radiation therapy within 4 week prior study entry No filgrastim ( GCSF ) within 24 hour study therapy No prior systemic chemotherapy metastatic disease Neoadjuvant adjuvant nontaxane chemotherapy 1 year prior study entry allow No concurrent local radiotherapy control pain lifethreatening situation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>